

02 January 2020

ASX Market Announcements Office
ASX Limited
Level 4, North Tower, Rialto
525 Collins Street
Melbourne VIC 3000

By electronic lodgement

Dear Ms Tang,

Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth)

Micro-X Limited (ASX:MX1) (ACN 153 273 735) (MX1) gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) (Act) that:

- (a) today it issued 2,500,000 fully paid ordinary shares at an issue price of \$0.40 per share upon conversion of 10,000 unlisted convertible notes issued by MX1 in April 2018;
- (b) the shares referred to above were issued without disclosure under Part 6D.2 of the Act;
- (c) as at the date of this notice, MX1 has complied with:
 - (i) the provisions of Chapter 2M of the Act as they apply to MX1; and
 - (ii) section 674 of the Act; and
- (d) as at the date of this notice, there is no “excluded information” of the type referred to in sections 708A(7) and 708A(8) of the Act that is required to be set out in this notice under section 708A(6)(e) of the Act.

Yours sincerely



Georgina Carpendale
Company Secretary
Micro-X Limited

– ENDS –

About Micro-X

Micro-X Limited (the **Company**) is an ASX listed hi-tech company developing and commercialising a range of innovative products for the global health and security markets, based on proprietary cold cathode, carbon nanotube emitter technology. The electronic control of emitters with this technology enables X-ray products with significant reduction in size, weight and power requirements, enabling greater mobility and ease of use in existing x-ray markets and a range of new and unique security and defence applications. The Company has its core R&D, engineering and production capability at its facility in Adelaide, Australia.

The Company's first product, the *Carestream DRX Revolution Nano*, is an ultra-lightweight digital medical x-ray system for the rapidly expanding mobile x-ray market in hospitals and healthcare. The *Carestream DRX Revolution Nano* holds 510(k) and CE Mark certifications and is sold commercially in a number of global markets by the Company's exclusive distributor, Carestream Health, Inc.. The Company has a portfolio of

innovative products in development, aimed at customer solutions where there is little or no competition. This includes the Mobile Backscatter Imager or MBI which will image Improvised Explosive Devices for security, defence and counter-terrorism applications. The MBI is being jointly developed in partnership with Thales, a global supplier of defence and security technology systems, who are providing technical support and \$10 million of funding.

CONTACTS

Micro-X Limited	Investor Enquiries
Peter Rowland Managing Director Tel: +61 8 7099 3966 E: admin@micro-x.com	David Allen / John Granger Hawkesbury Partners Tel: +61 2 9103 9494 E: dallen@hawkesburypartners.com